Novartis Venture Fund

Boston, Massachusetts
Our primary focus is on the development of novel therapeutics and platforms. We balance the therapeutic focus with investments in medical devices, diagnostics or drug delivery systems. In our investments we look for unmet need and clinical impact, novel proprietary science and understanding of mechanism, management and board experience and capitalefficiency in the program. We prefer to have our initial investment at the early stage to build the company and follow with additional investment in pace with the company:tm:s progress. We continue our approach of larger focused investments and anticipate total investments up to USD 30 to 50 mio per company over its life, but it can be as little as 100'000 USD to get started. We will increase our activities to lead or co-lead deals further and remain open to participate in larger syndicates.
Founded:1996
Firm Location:Boston, Massachusetts • Cambridge, Massachusetts • Basel, Switzerland • Zurich, Switzerland
Novartis Venture Fund Team
INVESTORSINTRO STRENGTHSWEET SPOT (RANGE)INVESTMENT LOCATIONSTOP INVESTMENT CATEGORIES
n/a
$7.5M
($5.0M - $10.0M)
Investors in Zurich (Switzerland), Investors in Europe
Investors in BioTech (Series A), Investors in Therapeutics (Series A), Investors in Pharmaceuticals (Series A), Investors in Pharmaceuticals (Seed), Investors in BioTech (Seed), Investors in Therapeutics (Seed)
+2
Photo of Laura Brass, Managing Director at Novartis Venture Fund
n/a
$7.5M
($5.0M - $10.0M)
Investors in Cambridge (MA)
Investors in Pharmaceuticals (Seed), Investors in BioTech (Seed), Investors in BioTech (Series A), Investors in Pharmaceuticals (Series A), Investors in BioTech (Seed), Investors in Pharmaceuticals (Seed), Investors in BioTech (Series A), Investors in Pharmaceuticals (Series A), Investors in Boston / New England (Other Lists)
+5
n/a
$7.5M
($5.0M - $10.0M)
Investors in Cambridge (MA)
Investors in BioTech (Series A), Investors in BioTech (Seed), Investors in BioTech (Seed), Investors in BioTech (Series A), Investors in Boston / New England (Other Lists)
+1
Photo of Bart Dzikowski, Managing Director at Novartis Venture Fund
n/a
$7.5M
($5.0M - $10.0M)
Investors in Europe, Investors in Basel (Switzerland)
Investors in BioTech (Series A), Investors in BioTech (Seed)
n/a
$7.5M
($5.0M - $10.0M)
Investors in Europe, Investors in Basel (Switzerland)
Investors in BioTech (Series A), Investors in Pharmaceuticals (Seed), Investors in Pharmaceuticals (Series A), Investors in BioTech (Seed)
Photo of Anja Konig, Managing Director at Novartis Venture Fund
n/a
$7.5M
($5.0M - $10.0M)
Investors in Basel (Switzerland)
Investors in Pharmaceuticals (Seed), Investors in BioTech (Seed), Investors in Pharmaceuticals (Series A), Investors in BioTech (Series A)
n/a
$7.5M
($5.0M - $10.0M)
Investors in Boston (MA)
Investors in BioTech (Series A), Investors in Pharmaceuticals (Seed), Investors in Pharmaceuticals (Series A), Investors in BioTech (Seed), Investors in BioTech (Seed), Investors in Pharmaceuticals (Seed), Investors in BioTech (Series A), Investors in Pharmaceuticals (Series A), Investors in Boston / New England (Other Lists)
+5
n/a
$7.5M
($5.0M - $10.0M)
Investors in Basel (Switzerland)
Investors in Pharmaceuticals (Seed), Investors in BioTech (Seed), Investors in BioTech (Series A), Investors in Pharmaceuticals (Series A)
Photo of Aaron Nelson, Managing Director at Novartis Venture Fund
n/a
$7.5M
($5.0M - $10.0M)
Investors in Cambridge (MA)
Investors in Chemicals (Seed), Investors in Therapeutics (Series A), Investors in BioTech (Series A), Investors in Chemicals (Series A), Investors in BioTech (Seed), Investors in BioTech (Seed), Investors in Chemicals (Seed), Investors in BioTech (Series A), Investors in Chemicals (Series A), Investors in Boston / New England (Other Lists), Investors in Therapeutics (Seed), Investors in Therapeutics (Seed), Investors in Therapeutics (Series A)
+9
n/a
$7.5M
($5.0M - $10.0M)
Investors in Boston (MA)
Investors in BioTech (Series A), Investors in Pharmaceuticals (Seed), Investors in Pharmaceuticals (Series A), Investors in BioTech (Seed), Investors in BioTech (Seed), Investors in Pharmaceuticals (Seed), Investors in BioTech (Series A), Investors in Pharmaceuticals (Series A), Investors in Boston / New England (Other Lists)
+5
Photo of Beat Steffen, Managing Director at Novartis Venture Fund
n/a
$7.5M
($5.0M - $10.0M)
Investors in Basel (Switzerland)
Investors in Pharmaceuticals (Seed), Investors in BioTech (Seed), Investors in Pharmaceuticals (Series A), Investors in BioTech (Series A)
Photo of Marianne Uteng, Managing Director at Novartis Venture Fund
n/a
$7.5M
($5.0M - $10.0M)
Investors in Basel (Switzerland), Investors in Europe
Investors in BioTech (Series A), Investors in Pharmaceuticals (Seed), Investors in Pharmaceuticals (Series A), Investors in BioTech (Seed)